Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19203405 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| SCHEMBL19203407 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| SCHEMBL20702038 | 0.87 | HCAR3 (0.43) | KDM4EALDH1A1SMN1; SMN2PCSK9HCRTR1 | |
| SCHEMBL19477571 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| Hydrochloric Acid SCHEMBL30361735 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| Hydrochloric Acid SCHEMBL28378737 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| Hydrochloric Acid SCHEMBL28378739 | 0.84 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| SCHEMBL20715568 | 0.80 | KDM4E (0.40) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| SCHEMBL12690881 | 0.74 | ALDH1A1 (0.58) | KDM4EALDH1A1SMN1; SMN2PCSK9HCAR3 | |
| SCHEMBL13663255 | 0.74 | TRPV4 (0.39) | KDM4EBCDIN3DHCRTR1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | claimed |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12441709-B2 | Therapeutic compounds | INDIVIOR UK LIMITED (GB) | 2025-10-14 | — | — | US | disclosed |
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2024-03-07 | — | — | US | disclosed |
| US-11753398-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753398-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | KDM4E 2777/4885ALDH1A1 1070/4885SMN1; SMN2 1337/4885 |
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | KDM4E 2777/4885ALDH1A1 1070/4885SMN1; SMN2 1337/4885 |
| US-12441709-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | KDM4E 2777/4885ALDH1A1 1070/4885SMN1; SMN2 1337/4885 |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | KDM4E 2094/4885ALDH1A1 3977/4885SMN1; SMN2 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.